Tumor-Associated Myeloid-Derived Suppressor Cells

Cancer Immunotherapy

Volumn , Issue , 2007, Pages 309-331

  Bunt, Stephanie K ^a   Hanson, Erica M ^a   Sinha, Pratima ^a   Srivastava, Minu K ^a   Clements, Virginia K ^a   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882475457     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012372551-6/50081-X     Document Type: Chapter

References (98)

1. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
2. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., Carbone D.P., Gabrilovich D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6:1755-1766.
3. Angulo I., Rodriguez R., Garcia B., Medina M., Navarro J., Subiza J.L. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-gamma. J. Immunol. 1995, 155:15-26.
4. Aoe T., Okamoto Y., Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med. 1995, 181:1881-1886.
5. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow?. Lancet 2001, 357:539-545.
6. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838-3846.
7. + T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 1999, 162:5728-5737.
8. Bronte V., Serafini P., Mazzoni A., Segal D.M., Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003, 24:302-306.
9. + cells. J. Immunol. 1998, 161:5313-5320.
10. Brys L., Beschin A., Raes G., Ghassabeh G.H., Noel W., Brandt J., Brombacher F., De Baetselier P. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J. Immunol. 2005, 174:6095-6104.
11. Bunt S.K., Sinha P., Clements V.K, Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006, 176:284-290.
12. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
13. Danna E.A., Sinha P., Gilbert M., Clements V.K., Pulaski B.A., Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004, 64:2205-2211.
14. de Jonge W.J., Kwikkers K.L., te Velde A.A., van Deventer S.J., Nolte M.A., Mebius R.E., Ruijter J.M., Lamers M.C., Lamers W.H. Arginine deficiency affects early B cell maturation and lymphoid organ development in transgenic mice. J. Clin. Invest. 2002, 110:1539-1548.
15. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., Del Soldato P., Melani C., Guiducci C., Colombo M.P., Iezzi M., Musiani P., Zanovello P., Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA 2005, 102:4185-4190.
16. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
17. Edelman M.J., Gandara D.R., Lau D.H., Lara P., Lauder I.J., Tracy D. Sequential combination chemotherapy in patients with advanced non-small-cell lung carcinoma: Carboplatin and gemcitabine followed by paclitaxel. Cancer 2001, 92:146-152.
18. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990, 323:1228-1233.
19. Finn O.J. Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 2003, 3:630-641.
20. Fleming T.J., Fleming M.L., Malek T.R. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the ly-6 family. J. Immunol. 1993, 151:2399-2408.
21. + regulatory T cells. Nat. Immunol. 2003, 4:330-336.
22. Gabrilovich D., Bronte V., Chen S.H., Colombo M.P., Ochoa A.C., Ostrand-Rosenberg S., Schreiber H. The terminology issue for myeloid-suppressor cells. Cancer Res. 2006, 67:245.
23. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
24. Gabrilovich D.I., Ciernik I.F., Carbone D.F. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 1996, 170:101-110.
25. Gabrilovich D.I., Nadaf S., Corak I., Berzofsky J.A., Carbone D.P. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol. 1996, 170:111-119.
26. Gabrilovich D.I., Velders M.P., Sotomayor E.M., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+myeloid cells. J. Immunol. 2001, 166:5398-5406.
27. + cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int. J. Cancer 1997, 73:663-669.
28. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006, 6:383-393.
29. Ghansah T., Paraiso K.H., Highfill S., Desponts C., May S., McIntosh J.K., Wang J.W., Ninos J., Bayer J., Cheng F., Sotomayor E., Kerr W.G. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J. Immunol. 2004, 173:7324-7330.
30. + regulatory T cell proliferation. J. Exp. Med. 2005, 202:919-929.
31. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005, 65:3437-3446.
32. Haas A.R., Sun J., Vachani A., Wallace A.F., Silverberg M., Kapoor V., Albelda S.M. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin. Cancer Res. 2006, 12:214-222.
33. Harris R.E., Chlebowski R.T., Jackson R.D., Frid D.J., Ascenseo J.L., Anderson G., Loar A., Rodabough R.J., White E., McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: Prospective results from the Women's Health Initiative. Cancer Res. 2003, 63:6096-6101.
34. Howe L.R., Subbaramaiah K., Patel J., Masferrer J.L., Deora A., Hudis C., Thaler H.T., Muller W.J., Du B., Brown A.M., Dannenberg A.J. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects a gainst human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002, 62:5405-5407.
35. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
36. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., Gabrilovich D. All-trans-retinoic acid elim inates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003, 63:4441-4449.
37. Kusmartsev S., Gabrilovich D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 2002, 51:293-298.
38. Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 2006, 55:237-245.
39. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 2004, 172:989-999.
40. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 2000, 165:779-785.
41. Lathers D.M., Clark J.I., Achille N.J., Young M.R. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D. Cancer Immunol. Immunother. 2004, 53:422-430.
42. 3) treatment to diminish suppressor cells in head and neck cancer patients. Hum. Immunol. 2001, 62:1282-1293.
43. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 1998, 16:137-161.
44. + cells in the development of antitumor immunity. Cancer Res. 2004, 64:1130-1139.
45. MacDonald K.P., Rowe V., Clouston A.D., Welply J.K., Kuns R.D., Ferrara J.L., Thomas R., Hill G.R. Cytokine expanded myeloid precur- sors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J. Immunol. 2005, 174:1841-1850.
46. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
47. + regulatory T cells. J. Exp. Med. 2005, 201:1061-1067.
48. Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P., Zanovello P., Segal D.M. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 2002, 168:689-695.
49. Melani C., Chiodoni C., Forni G., Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102:2138-2145.
50. +) progenitors, by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998, 92:4778-4791.
51. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A., Frost T., Lush R., Antonia S., Gabrilovich D. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66:9299-9307.
52. + regulatory T cells. J. Immunol. 2004, 173:4433-4442.
53. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Binl, potentiates cancer chemotherapy. Nat. Med. 2005, 11:312-319.
54. Muller A.J., Prendergast G.C. Marrying immunotherapy with chemotherapy: Why say IDO?. Cancer Res. 2005, 65:8065-8068.
55. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., Iove R., Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004, 172:464-474.
56. Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S.M., Gabrilovich D.I. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005, 65:9525-9535.
57. Oyama T., Ran S., Ishida T., Nadaf S., Kerr L., Carbone D.P., Gabrilovich D.I. Vascular endothelial growth factor affects dendritic, cell maturation through the inhibition of nuclear factorkappa B activation in hemopoietic progenitor cells. J. Immunol. 1998, 160:1224-1232.
58. +) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res 1995, 1:95-103.
59. Pelaez B., Campillo J.A., Lopez-Asenjo J.A., Subiza J.L. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J. Immunol. 2001, 166:6608-6615.
60. Pericle F., Kirken R.A., Bronte V., Sconocchia G., DaSilva L., Segal D.M. Immunocom-promised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J. Immunol. 1997, 159:2580-2585.
61. Porembska Z., Luboinski G., Chrzanowska A., Mielczarek M., Magnuska J., Baranczyk-Kuzma A. Arginase in patients with breast cancer. Clin. Chim. Acta 2003, 328:105-111.
62. Porembska Z., Skwarek A., Mielczarek M., Baranczyk-Kuzma A. Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma. Cancer 2002, 94:2930-2934.
63. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., Gilbert J., Ochoa A.C. Arginasel in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 2005, 202:931-939.
64. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B., Ochoa A.C. Arginase 1 production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptorexpression and antigen-specific T-cell responses. Cancer Res. 2004, 64:5839-5849.
65. Roh J.L., Sung M.W., Park S.W., Heo D.S., Lee D.W., Kim K.H. Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res 2004, 64:3230-3235.
66. Rossner S., Voigtlander C., Wiethe C., Hanig J., Seifarth C., Lutz M.B. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 2005, 35:3533-3544.
67. Saito H., Tsujitani S., Ikeguchi M., Maeta M., Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 1998, 78:1573-1577.
68. Salvadori S., Martinelli G., Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 2000, 164:2214-2220.
69. Schmidt-Wolf I.G., Dejbakhsh-Jones S., Ginzton N., Greenberg P., Strober S. T-cell subsets and suppressor cells in human bone marrow. Blood 1992, 80:3242-3250.
70. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001, 61:4756-4760.
71. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocytemacrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64:6337-6343.
72. Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., Zanovello P., Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 2004, 53:64-72.
73. Seung L.P., Rowley D.A., Dubey P., Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. USA 1995, 92:6254-6258.
74. + T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163:5211-5218.
75. Sinha P., Clements V.K., Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 2005, 174:636-645.
76. Sinha P., Clements V.K., Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune, surveillance against metastasis. Cancer Res. 2005, 65:11743-11751.
77. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin EZ promotes tumor progression by inducing myeloid-derired suppressor cells. Cancer Res 2007, In press.
78. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 2005, 175:8200-8208.
79. + myeloid progenitor cells that differentiate in vivo into resting dendritic cells. Diabetes 2005, 54:434-442.
80. Strober S. Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: Exploring obscure relationships. Annu. Rev. Immunol. 1984, 2:219-237.
81. Sugiura K., Inaba M., Ogata H., Yasumuzu R., Sardina E.E., Inaba K., Kuma S., Good R.A., Ikehara S. Inhibition of tumor cell proliferation by natural suppressor cells present in murine bone marrow. Cancer Res. 1990, 50:2582-2586.
82. + myeloid suppressor cells in tumor-bearing, animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
83. Tas M.P., Simons P.J., Balm F.J., Drexhage H.A. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: In vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol. Immunother. 1993, 36:108-114.
84. Taylor A., Verhagen J., Blaser K., Akdis M., Akdis C.A. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells. Immunology 2006, 117:433-442.
85. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., Letterio J.J., Paul W.E., Berzofsky J.A. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CDId-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J. Exp. Med. 2003, 198:1741-1752.
86. Valente J.F., Ogle C.K., Alexander J.W., Li B.G., Custer D.A., Noel J.G., Ogle J.D. Bone marrow and splenocyte coculture-generated cells enhance allograft survival. Transplantation 1997, 64:114-123.
87. + cells increases the effectiveness of adoptive immunotherapy. J. Immunother. 2000, 23:115-124.
88. + cells in tumorbearing host directly promotes tumor an giogenesis. Cancer Cell 2004, 6:409-421.
89. +) progenitor cells. Hum. Immunol. 2001, 62:332-341.
90. Young M.R., Wright M.A., Coogan M., Young M.E., Bagash J. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol. Immunother 1992, 35:14-18.
91. + natural suppressor cells. Int. J. Cancer 1997, 74:69-74.
92. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A.C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res. 2005, 65:3044-3048.
93. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
94. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
95. Rodriguez P.C., Ochoa A.C. T cell dysfunction in cancer: Role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin. Cancer Biol. 2006, 16:66-72.
96. Shacter E., Weitzman S.A. Chronic inflammation and cancer. Oncology (Williston Park) 2002, 16:217-226.
97. Shacter E., Weitzman S.A. Chronic inflammation and cancer. Oncology (Williston Park) 2002, 16:229. discussion, 230-212.
98. Whiteside T.L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16:3-15.